A large national database study presented at CROI 2026 in Denver, CO, reports that 5-year survival remains lower for people with HIV compared with people without HIV across most treatment modalities for...
A multicenter randomized trial has demonstrated that the NeuroSAFE technique significantly improves erectile function and accelerates early urinary continence recovery following robot-assisted radical...
In a multicenter diagnostic study, artificial intelligence assistance significantly improved radiologists’ ability to detect clinically significant prostate cancer on MRI—enhancing sensitivity, specificity,...
The FDA announced the approval of darolutamide for treating metastatic castration-sensitive prostate cancer. This review was conducted under Project Orbis, which allows for concurrent submission and review...
Darolutamide monotherapy reduced prostate-specific antigen response in patients with hormone-sensitive prostate cancer while maintaining testosterone levels in a recent 24-week randomized study.
A new retrospective study examines treatment trends among men with limited life expectancy diagnosed with prostate cancer in the Veterans Affairs health system from 2000 to 2019. Researchers explored...
A team of researchers compared the presence of short-term side effects using two image-guided radiation treatment—magnetic resonance imaging-guided daily adaptive prostate stereotactic body radiotherapy...
Hypercholesterolemia and diabetes have a minimal impact on major adverse cardiovascular events (MACE) risk in patients with prostate cancer (PCa) who are treated with androgen deprivation therapy (ADT),...
The researchers set out to determine whether neoadjuvant novel hormonal agent (NHA) therapy before radical prostatectomy can improve outcomes in men with high-risk prostate cancer.
Study findings presented at the 2022 ASCO Annual Meeting reveal oncologists’ and urologists’ reasons for underutilization of treatment intensification for patients with metastatic castration–sensitive...
